Consorcio Hospitalario Provincial De Castellon

The Medical Oncology department at Consorcio Hospitalario Provincial De Castellon concentrates on advanced prostate cancer research, aiming to improve survival and quality of life for men with resistant disease.

• Castration‑Resistant Prostate Cancer
• Metastatic hormone‑sensitive prostate cancer
• High‑risk NM‑CRPC
• Bone‑dominant metastatic prostate disease

Ongoing studies compare standard chemotherapy with targeted radiopharmaceuticals such as Radium‑223, evaluate next‑generation androgen‑axis inhibitors like apalutamide, and assess novel combination regimens to delay disease progression.

Across a broad spectrum of neoplasms, the site conducts trials that test new targeted therapies, immunotherapies, and precision‑medicine approaches to enhance outcomes for patients with breast, ovarian, and lymphoid cancers.

• Breast Cancer (HR‑positive/HER2‑negative, HER2‑positive, Triple‑Negative)
• Ovarian and fallopian tube cancer
• Diffuse Large B‑Cell Lymphoma
• Follicular Lymphoma
• Pancreatic adenocarcinoma with CLDN18.2 expression

Trials evaluate combinations such as olaparib with immunotherapy, compare antibody‑drug conjugates like trastuzumab deruxtecan versus T‑DM1, and test adjuvant PARP inhibition to reduce invasive disease‑free recurrence in high‑risk breast cancer.

The department’s respiratory research targets both non‑small‑cell and small‑cell lung cancers, focusing on novel immuno‑oncology agents and strategies to overcome resistance and brain metastases.

• Non‑Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer
• NSCLC with brain metastasis
• PD‑L1‑high metastatic NSCLC
• Urothelial carcinoma with lung involvement

Current studies assess the benefit of adding tiragolumab to checkpoint inhibition, compare novel PD‑L1 blockers such as durvalumab plus chemotherapy, and explore maintenance immunotherapy after chemoradiation in unresectable disease.